Genetic Technologies Limited (ADR) (NASDAQ:GENE)

CAPS Rating: 1 out of 5

A biotechnology company, pursuing commercial opportunities in: out-licensing its non-coding patents globally; expanding genetic service-testing business in the Asia-Pacific Region; & supporting research projects in which it is already involved.

Results 1 - 8 of 8

Recs

0
Member Avatar pchop12316 (57.83) Submitted: 1/21/2015 3:39:59 PM : Underperform Start Price: $1.64 GENE Score: +18.25

not this one

Recs

0
Member Avatar TSIF (99.96) Submitted: 1/20/2015 10:39:21 AM : Underperform Start Price: $2.00 GENE Score: +34.07

Nothing personal here, or nothing that hasn't been said multiple times in the past. Just noticed this one again after the 1:5 reverse split, (which I did report this morning). Was hanging at about $0.40, so historically, $2.00 is not out of line based on past valuation. In many cases reverse splits result in declines as people notice the little bugger in their portfolio that they had already written off and decide to finally eradicate it. Testing for Brest cancer would be a good tool....proving effectiveness and getting it adopted is a little bit more than this Australian based ADR, small cap can handle.

Recs

0
Member Avatar KimLanners (< 20) Submitted: 9/8/2014 1:06:42 PM : Underperform Start Price: $3.30 GENE Score: +61.33

cash flow is not good

Recs

0
Member Avatar red1582 (28.99) Submitted: 11/16/2012 11:52:49 AM : Underperform Start Price: $12.90 GENE Score: +140.37

100% Sell Signal
Gaped Down

Recs

1
Member Avatar MarkSmithJr777 (< 20) Submitted: 7/20/2011 7:34:41 PM : Underperform Start Price: $38.50 GENE Score: +149.20

Coming down

Recs

0
Member Avatar ferdicemara (< 20) Submitted: 5/15/2011 11:38:11 AM : Outperform Start Price: $38.65 GENE Score: -150.31

success

Recs

0
Member Avatar Lifeguru (67.69) Submitted: 4/9/2007 5:00:09 PM : Underperform Start Price: $35.50 GENE Score: +145.10

Junk

Recs

0
Member Avatar ctolbert (75.67) Submitted: 4/6/2007 7:39:22 PM : Underperform Start Price: $29.55 GENE Score: +144.01

Genetics companies are a hard sell and are too susceptible to market news to bank on.

Results 1 - 8 of 8

Featured Broker Partners


Advertisement